Stock Analiz

REGENXBIO Inc. RGNX

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2015 · data as of November 13, 2026

$7.64Market cap $505M
Open the interactive analysis →

REGENXBIO Inc. (RGNX) is a healthcare company listed in the US with a market value of about $505M. In the twelve months to September 30, 2026 it had revenue of $154M and net income of -$175M, a net margin of -113.9%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 2% a year, a 5-year average ROIC of -51%.

About REGENXBIO

REGENXBIO is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2015. Revenue went from $6M in 2014 to $170M in 2025, growth of about 35.3% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 20% over three years (dilution for shareholders). It spends 134% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth4/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.3
P/B3.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-30.6%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)104.5%
Revenue growth (5 yrs, per year)2.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-180.0%
ROIC (5-yr avg.)-50.5%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$154M$170M$83M$90M$113M$470M$155M$35M$219M$10M$5M
Net income-$175M-$194M-$227M-$263M-$280M$128M-$111M-$95M$100M-$73M-$63M
Free cash flow-$155M-$126M-$176M-$228M-$238M$135M-$81M-$119M$91M-$65M-$57M
EPS (diluted)$-3.21$-3.76$-4.59$-6.02$-6.50$2.91$-2.98$-2.58$2.73$-2.45$-2.38
Net margin-113.9%-113.8%-272.5%-292.0%-248.7%27.2%-72.0%-268.9%45.7%-704.0%-1372.1%
ROIC—-91.5%-68.3%-66.8%-43.0%17.0%-20.9%-31.4%16.6%-41.5%-40.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 10 analysts is $21.40, 180% above the current price; targets range from $12.00 to $42.00; the consensus rating is “Strong buy”; expected EPS is $-3.58 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does REGENXBIO pay a dividend?

Not currently.

Is REGENXBIO a good stock to buy?

We do not give buy or sell advice. REGENXBIO scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.